Identifying the most cost-effective screening strategy for CRC can inform health care professionals as to which screening strategy to recommend for patients, and, thus, reduce the cost and maximize the effectiveness of CRC screening.
The purpose of this study was to conduct a systematic review, similar to the review of Lansdorp-Vogelaar et al, 7 of the cost-effectiveness analyses of various CRC screening strategies. In contrast to the review of Lansorp-Vogelaar et al, 7 this current review focuses on cost-effectiveness analyses conducted in the United States alone since May 2007. Our review examined the following questions:
1. How does the cost effectiveness of current CRC screening strategies compare with no screening?
Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths among both men and women in the United States, and 132,700 estimated new cases of CRC and 49,700 CRC-related deaths will occur in the United States in 2015. 1 The use of CRC screening tests can reduce the incidence and mortality of the disease through early detection so that the cancer can be removed before it progresses. 7 years to assess the cost effectiveness of the most up-to-date screening strategies used in the clinical setting. (The review by Lansorp-Vogelaar et al 7 assessed studies up to January 2010.)
In PubMed, we searched for terms such as "colorectal screening" and "cost analysis," and limited our search to English-language studies published May 2007 or later. This search identified 529 studies. The Cost-Effectiveness Analysis Registry was searched for the term "colorectal cancer screening," for which 5 studies were identified with the same limitations as mentioned above. The York Database of Abstracts of Reviews of Effects was searched using the search terms "colorectal" and "cost," for which 3 additional studies were identified using the same limitations. The reference list of the review by Lansdrop-Vogelaar et al, 7 which analyzed the cost effectiveness of CRC screening tests from 23 studies, was manually searched to identify studies not gathered by the database searches.
By evaluating information found in the titles, abstracts, and full texts of the studies gathered from the database searches, we excluded unoriginal studies, those that did not analyze at least 1 of the screening tests for CRC we were assessing, those that lacked an analysis of cost-effectiveness analysis, and those that analyzed special groups ineligible for routine screening. In contrast to previous reviews, we excluded studies that did not analyze a US population or report the cost in US dollars. We used these criteria for exclusion because the difference in price structures among health care systems in different countries makes a cross-comparison of the screening strategies uninformative. Collective agreement by the authors determined whether a study should be included if there was uncertainty.
Comparing the Cost Effectiveness of Current Screening Strategies With No Screening
A paired comparison of each screening strategy with no screening (eg, annual Hemoccult II [Beckman Coulter, Brea, California] vs no screening) across each of the studies was conducted to answer this question. The differences in expected costs per person and the differences in life-years gained (LYGs) per person for each paired comparison were examined. If one strategy was less costly and more effective than no screening, then it was characterized as being dominant. The incremental cost-effectiveness ratios (ICERs) were examined for nondominated strategies using the following equation: These screening tests were chosen due to their inclusion in the CRC screening guidelines from the USPSTF. 6 Some studies specified whether sigmoidoscopy was followed with biopsy or not. Screening strategies from studies were eliminated if they were not distinct (eg, individualized colonoscopies). If a study did not specify the type of annual fecal occult blood test, then we assumed that the test was the annual Hemoccult II. If a study evaluated virtual colonoscopy, then cost and effectiveness estimates pertaining to extracolonic findings were eliminated. The commonly cited threshold of $50,000/LYG was set for assessing cost effectiveness.
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Assessing the Consistency of Study Findings
We conducted a series of paired comparisons of the results reported in each of the studies included in this review. The differences in expected costs per person and the differences in LYG per person for each paired comparison were examined. The ICERs were examined for nondominated strategies using the following equation: If strategy A was less costly and more effective than strategy B, then strategy A was characterized as dominant.
A threshold of $50,000/LYG was set for assessing cost effectiveness. The same strategies were similarly evaluated as in the first study question except for virtual colonoscopy and the stool DNA test. These 2 strategies were not included because the compar-isons were limited and their associated costs were higher than other screening strategies.
Results
Identification of Cost-Effectiveness Analyses
The search for relevant articles was initiated in February 2014; we were able to identify 543 studies. After analyzing the title of the studies, 267 of those studies were included in our analysis. After analyzing the abstracts of those studies, we chose 125 to include in our review, and their full texts were analyzed. Of these, 17 studies met the criteria for inclusion (Fig) .
Each data element abstracted from each of the included studies can be found in Tables 1 and 2. 9-26 Table 1 lists the perspective taken, models used, strategies evaluated, and basic results for each study. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] If a study used more than 1 model, then an additional entry was made in Table 1 for the given study. Table 2 provides further details, particularly on the sensitivity and specificity rates, costs for tests, and the types of sensitivity analyses performed. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This review includes 13 studies not included in the review published in 2011 by Lansdorp-Vogelaar et al. 
Cost Effectiveness of Current Screening Strategies vs No Screening
For 34% of comparisons made, CRC screening -regardless of the strategy evaluated -was less costly and more effective than no screening. The highest ICER, which was for stool DNA testing every 5 years, was $34,258 per life-year saved; nearly all other screening strategies had ICERs below $20,000/ LYG compared with no screening. The complete results of this analysis are provided in the Supplemental Table (online). [9] [10] [11] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Hemoccult II was less costly and more effective than no screening in 89% of the comparisons made. The annual Hemoccult SENSA and annual fecal immunochemical strategies either dominated no screening or had an ICER below $1,000/LYG. Overall, 60% and 78% of comparisons made showed that Hemoccult SENSA and an annual fecal immunochemical test, respectively, were less costly and more effective than no screening at all.
Sigmoidoscopy every 5 years either dominated no screening or had an ICER below $2,000/LYG. Overall, 64% of comparisons made showed that undergoing sigmoidoscopy every 5 years was less costly and more effective than no screening. Sigmoidoscopy every 5 years in combination with any annual fecal occult blood test (annual Hemoccult II or annual Hemoccult SENSA) either dominated no screening or had an ICER below $15,000/LYG. Approximately 50% of comparisons made showed that sigmoidoscopy every 5 years plus any annual fecal occult blood test was less costly and more effective than no screening. Approximately 44% of comparisons made also showed that sigmoidoscopy every 5 years plus an annual ecal immunochemical test was less costly and more effective than no screening. Sigmoidoscopy every 10 years had an ICER below $10,000/LYG.
Colonoscopy every 10 years beginning at 50 years of age either dominated no screening or had an ICER below $28,000/LYG. Overall, 18% of comparisons made showed that undergoing colonoscopy every 10 years was less costly and more effective than no screening. Virtual colonoscopy every 5 years did not dominate no screening in This study also included data from Sonnenberg et al. 15 aFIT = annual fecal immunochemical test, aHemII = annual Hemoccult II, aHemSENSA = annual Hemoccult SENSA, COL10 = colonoscopy every 10 y, COL 10/40 = colonoscopy every 10 y starting at age 40 y, CRC-SPIN = colorectal cancer-simulated population model for incidence and natural history, CTC5 = computed tomography colonography every 5 y, CTC10 = computed tomography colonography every 10 y, CTC10/2D = 2-dimensional computed tomography colonography every 10 y, CTC10/3D = 3-dimensional computed tomography colonography every 10 y, CTC10/ER/with CAD = computed tomography colonography with a computer-aided design every 10 y (read by an experienced radiologist), CTC10/IR/with CAD = computed tomography colonography with a computer-aided design every 10 y (read by an inexperienced radiologist), DNA2 (SEPT9-2-well) = stool DNA test using 2-well methylated Septin 9 DNA assays every 2 y, DNA3 = stool DNA test every 3 y, DNA5 = stool DNA test every 5 y, MISCAN = microsimulation screening analysis, NS = no screening, SIG5 = sigmoidoscopy every 5 y, SIG10 = sigmoidoscopy every 10 y, SIGB5 = sigmoidoscopy with biopsy every 5 y, SimCRC = simulation model of colorectal cancer. any study, but it had an ICER below $22,000/ LYG. Virtual colonoscopy every 10 years dominated no screening in 1 study, 9 and the data from the rest of the studies reported an ICER below $23,000/LYG. Stool DNA testing every 3 years or 5 years did not dominate a no-screening strategy in any study, but these 2 strategies had an ICER below $35,000/LYG.
Cost Effectiveness of Different Screening Strategies
When annual fecal immunochemical testing was compared with annual Hemoccult II testing, annual fecal immunochemical testing was either dominant or had an ICER below $50,000/LYG in 100% of the simulations from 5 different studies (Table 3) . By contrast, annual Hemoccult SENSA testing dominated annual fecal immunochemical testing in 100% of the simulations from 2 different studies (see Table 3 ). The majority of comparisons made between sigmoidoscopy every 5 years and annual Hemoccult SENSA or fecal immunochemical testing showed that sigmoidoscopy every 5 years dominated in 100% of the simulations. When compared with annual Hemoccult II, sigmoidoscopy every 5 years had an ICER below $50,000/LYG in 70% of the simulations from 5 different studies (see Table 3 ). When sigmoidoscopy every 5 years plus any annual fecal occult blood test (Hemoccult II, Hemoccult SENSA, fecal immunochemical test) was compared with annual fecal occult blood testing alone or sigmoidoscopy alone every 5 years, sigmoidoscopy every 5 years plus any annual fecal occult blood test had an ICER below $50,000/LYG or dominated the other strategy in 99% of the simulations. The majority of simulations showed that sigmoidoscopy every 5 years plus annual Hemoccult SENSA testing either dominated or had an ICER below $50,000/LYG when compared with sigmoidoscopy every 5 years plus annual Hemoccult II testing. When comparing sigmoidoscopy every 5 years plus annual fecal immunochemical testing with sigmoidoscopy every 5 years plus either annual Hemoccult II or Hemoccult SENSA testing, the simulations showed that sigmoidoscopy plus annual fecal immunochemical testing had an ICER below $50,000/LYG in 27% of the simulations.
Colonoscopy every 10 years had an ICER below $50,000/LYG in 74% of the simulations when compared with any type of annual fecal blood testing. d Number of studies with less than or more than $50,000/LYG = given a X vs Y comparison, the number of simulations resulting in X having an incremental cost effectiveness ratio less than or greater than $50,000/LYG when compared with Y. is cost effective when compared with no screening. Evidence suggests any of the current screening strategies will reduce mortality when compared with no screening. For 34% of the comparisons made, CRC screening -regardless of the strategy evaluated -was less costly and more effective than no screening. The highest ICER calculated was approximately $35,000/LYG, and the corresponding screening strategy was stool DNA test (v 1.0) every 5 years. This strategy was still below the typical cost-effectiveness threshold.
In addition, the current review confirms that uncertainty still exists as to which screening strategy is optimal in terms of cost effectiveness. Potential reasons for the disagreement among studies as to which screening strategy is the most cost effective have been explained by previous reviews on the cost effectiveness of CRC screening strategies. 7, 9 Each study uses a separate model to simulate the natural history of CRC. However, Knudsen et al 16 used 3 different models -microsimulation screening analysis, a simulation model of CRC, and a CRC-simulated population model for incidence and natural history -in their cost-effective analysis. The calculated ICERs between models were similar regardless of screening strategy; microsimulation screening analysis had a slightly higher ICER. In general, the decision analysis model used by Ladabaum et al 17 reported results similar to other studies that used the Markov and Archimedes models. The use of different model inputs, such as dwell time of precancerous and cancerous phases, screening test costs, or screening adherence, may be potential factors for disagreement among studies. The sensitivity and specificity rates of screening tests also vary among studies, thus posing yet another potential reason for different results.
It is clear that sigmoidoscopy every 5 years plus annual fecal occult blood testing is cost effective when compared with either strategy alone. Colonoscopy every 10 years is cost effective when compared with annual fecal occult blood testing or sigmoidoscopy every 5 years. However, the results are mixed when colonoscopy every 10 years is compared with sigmoidoscopy every 5 years plus any annual fecal occult blood test.
Patients aged 50 years who have an average risk of CRC must be advised by their health care professional as to which screening strategy is cost effective. Based on this review, any screening strategy is more cost effective compared with no CRC screening, and high-quality evidence supports this recommendation. Furthermore, colonoscopy every 10 years or sigmoidoscopy every 5 years plus any annual fecal occult blood test should be the first 2 screening strategies recommended to patients, but evidence is of moderate quality to support this recommendation. Obviously, each screening strategy has its own advantages. Colonoscopy is more sensitive and allows access to the rectum and the entire colon, whereas sigmoidoscopy has fewer risks of complications and does not require sedation or extensive bowel preparation.
Limitations
Data extracted from each study came from simulations that assumed 100% adherence of using each screening strategy. Clinically, this does not reflect the actual adherence rate. An important gap in the literature is the need to incorporate compliance rates into cost-effectiveness estimations. It is likely that different screening strategies should be recommended to different patients, based on predicted adherence rates, or that health care professionals present their patients with different options for screening strategies.
Another limitation of this study is that we included studies of US patients alone and did not include international study populations. Due to the relative differences in prices between countries, the cost-effectiveness data from this review cannot be applied to other CRC screening strategies in other countries.
Conclusions
Solid agreement exists among all the studies reviewed that colorectal cancer screening is either dominant or cost effective compared with no screening at all, regardless of the screening strategy employed. We found considerable variation concerning which screening strategies would be preferred, subject to a prespecified level of cost per life-year gained deemed acceptable.
